{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T21:42:02Z","timestamp":1781214122888,"version":"3.54.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,14]],"date-time":"2015-07-14T00:00:00Z","timestamp":1436832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","gastrojournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1053\/j.gastro.2015.07.001","type":"journal-article","created":{"date-parts":[[2015,7,11]],"date-time":"2015-07-11T09:13:36Z","timestamp":1436606016000},"page":"971-980.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in\u00a0an\u00a0Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis"],"prefix":"10.1053","volume":"149","author":[{"given":"Eric","family":"Lawitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mih\u00e1ly","family":"Makara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulus Salih","family":"Akarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Thuluvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana Lucia","family":"Preotescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Varunok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa M\u00aa.","family":"Morillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coleen","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloufar","family":"Mobashery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Redman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tami","family":"Pilot-Matias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regis A.","family":"Vilchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"H\u00e9zode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2015.07.001_bib1","unstructured":"World Health Organization. Hepatitis C. WHO fact sheet 164. Available at: http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/. Accessed September 9,\u00a02015."},{"key":"10.1053\/j.gastro.2015.07.001_bib2","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2015.07.001_bib3","unstructured":"World Health Organization. Global alert and response (GAR): hepatitis C. Available at: http:\/\/www.who.int\/csr\/disease\/hepatitis\/whocdscsrlyo2003\/en\/. Accessed September 9,\u00a02015."},{"key":"10.1053\/j.gastro.2015.07.001_bib4","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","article-title":"Diagnosis, management, and treatment of hepatitis C","volume":"39","author":"Strader","year":"2004","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2015.07.001_bib5","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection","volume":"361","author":"McHutchison","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2015.07.001_bib6","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2015.07.001_bib7","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2015.07.001_bib8","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2015.07.001_bib9","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2015.07.001_bib10","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2014.03.051","article-title":"Effectiveness of\u00a0telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis","volume":"147","author":"Hezode","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2015.07.001_bib11","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2015.07.001_bib12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1306227","article-title":"Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1","volume":"370","author":"Kowdley","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2015.07.001_bib13","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2015.07.001_bib14","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2015.07.001_bib15","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2015.07.001_bib16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.gastro.2014.04.045","article-title":"ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection","volume":"147","author":"Andreone","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2015.07.001_bib17","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"Ferenci","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2015.07.001_bib18","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2015.07.001_bib19","unstructured":"Sulkowski MS, Nelson DR, Wedemeyer H, et\u00a0al. Low frequency of anemia in phase 3 trials of ABT-450\/r\/ABT-267 and ABT-333 with ribavirin in treatment-na\u00efve (SAPPHIRE-I) and treatment-experienced (SAPPHIRE-II) patients, In 20th International AIDS Conference, Melbourne, Australia, July 20-25,\u00a02014."},{"key":"10.1053\/j.gastro.2015.07.001_bib20","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1001\/jama.2015.3868","article-title":"Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis","volume":"313","author":"Muir","year":"2015","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2015.07.001_bib21","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2015.07.001_bib22","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(14)61795-5","volume":"385","author":"Lawitz","year":"2015","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2015.07.001_bib23","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1021\/jm401398x","article-title":"Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A","volume":"57","author":"DeGoey","year":"2014","journal-title":"J\u00a0Med Chem"},{"key":"10.1053\/j.gastro.2015.07.001_bib24","first-page":"53","article-title":"Pharmacokinetics and tolerability of the HCV protease inhibitor ABT-450 following single ascending doses in healthy adult volunteers with and without ritonavir (HEP DART 2009 abstract 57)","volume":"5","author":"Menon","year":"2009","journal-title":"Glob Antiviral J"},{"key":"10.1053\/j.gastro.2015.07.001_bib25","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Feld","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2015.07.001_bib26","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2015.07.001_bib27","first-page":"1131A","article-title":"SVR12 rate of 98.6% in 992 HCV genotype 1b-infected patients treated with ABT-450\/r\/ombitasvir and dasabuvir with or without ribavirin","volume":"60","author":"Colombo","year":"2014","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2015.07.001_bib28","first-page":"1145A","article-title":"Safety of ABT-450\/r\/ombitasvir\u00a0+ dasabuvir with or without ribavirin in HCV genotype 1-infected patients: results from phase 2 and phase 3 trials","volume":"60","author":"Fried","year":"2014","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2015.07.001_bib29","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2013.10.019","article-title":"Randomized trial of daclatasvir and asunaprevir with or without PegIFN\/RBV for hepatitis C virus genotype 1 null responders","volume":"60","author":"Lok","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2015.07.001_bib30","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(14)61059-X","article-title":"All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2015.07.001_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","article-title":"Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial","volume":"163","author":"Zeuzem","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2015.07.001_bib32","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.gastro.2013.10.057","article-title":"Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection","volume":"146","author":"Everson","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2015.07.001_bib33","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1001\/jama.2015.3860","article-title":"Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection","volume":"313","author":"Poordad","year":"2015","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2015.07.001_bib34","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/hep.27705","article-title":"Randomized trial of interferon- and ribavirin-free ombitasvir\/paritaprevir\/ritonavir in treatment-experienced hepatitis C virus-infected patients","volume":"61","author":"Chayama","year":"2015","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2015.07.001_bib35","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 2","key":"10.1053\/j.gastro.2015.07.001_bib36","first-page":"S222","article-title":"Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir\/r-, ombitasvir- and dasabuvir-based regimens","volume":"62","author":"Krishnan","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2015.07.001_bib37","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/jmv.24255","article-title":"Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy","volume":"87","author":"Yoshimi","year":"2015","journal-title":"J\u00a0Med Virol"},{"key":"10.1053\/j.gastro.2015.07.001_bib38","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3109\/00498254.2010.519061","article-title":"The metabolism and disposition of a potent inhibitor of hepatitis C virus NS3\/4A protease","volume":"40","author":"Monteagudo","year":"2010","journal-title":"Xenobiotica"},{"key":"10.1053\/j.gastro.2015.07.001_bib39","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2015.07.001_bib40","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJM200012073432302","article-title":"Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis","volume":"343","author":"Heathcote","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2015.07.001_bib41","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1056\/NEJM200012073432301","article-title":"Peginterferon alfa-2a in patients with chronic hepatitis C","volume":"343","author":"Zeuzem","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2015.07.001_bib42","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2013.04.035","article-title":"Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)\u2014NCT01514890","volume":"59","author":"Hezode","year":"2013","journal-title":"J\u00a0Hepatol"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508515009361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508515009361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T00:53:46Z","timestamp":1537491226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508515009361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0016508515009361"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2015.07.001","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in\u00a0an\u00a0Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2015.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}